National Wilm's Tumor Study Late Effects
18 Years
85 Years
Both
Wilm's Tumor
Trial Information
National Wilm's Tumor Study Late Effects
The Late Effects Study is being conducted in order to answer scientific questions and to
serve as a resource for Wilms tumor patients and their families. Although most people in
this study enjoy good health, some may be at risk for certain health conditions. We are
collecting information from as many participants as possible in order to determine if they
or their offspring are at risk for adverse medical conditions. If there is more than one
case of Wilms tumor in a given family, we plan to work with geneticists to try to estimate
heritability and recurrence risks.
Inclusion Criteria:
Previously enrolled in NWTS 5.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
Outcome Measure:
To determine if survivors from Wilms tumors or their offspring are at risk for adverse medical conditions.
Outcome Time Frame:
1 year after closure of study
Safety Issue:
No
Principal Investigator
Howard Katzenstein, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Children's Healthcare of Atlanta
Authority:
United States: Food and Drug Administration
Study ID:
199-96
NCT ID:
NCT00228696
Start Date:
September 2005
Completion Date:
December 2011
Related Keywords:
- Wilm's Tumor
- late effects
- Wilms Tumor
Name | Location |
|---|---|
| Children's Healthcare of Atlanta | Atlanta, Georgia 30342 |
